Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3

Seminars in Thrombosis and Hemostasis

Volumn 32, Issue 6, 2006, Pages 636-645

  Michiels, Jan J ^a,b   Gadisseur, Alain ^a   Van Der Planken, Marc ^a   Schroyens, Wilfried ^a   Van De Velden, Ann ^a   Berneman, Zwi ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b Goodheart Institute   (Netherlands)

Author keywords

Bleeding time; Desmopressin (DDAVP); Ristocetin cofactor activity; Von Willebrand collagen binding activity; Von Willebrand disease; Von Willebrand factor; Von Willebrand factor concentrates

Indexed keywords

ALPHA 250; ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; COLLAGEN; DESMOPRESSIN; FACTOR 8Y; INNOBRAND; RISTOCETIN; TRANEXAMIC ACID; VON WILLEBRAND FACTOR; WILFACTIN;

BLEEDING; BLEEDING TIME; BLOOD CLOTTING FACTOR DEFICIENCY; BLOOD SAMPLING; CLINICAL PRACTICE; COMPARATIVE STUDY; HUMAN; MAJOR SURGERY; MINOR SURGERY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; THROMBOCYTE FUNCTION; TREATMENT INDICATION; TREATMENT OUTCOME; VON WILLEBRAND DISEASE;

COAGULANTS; DEAMINO ARGININE VASOPRESSIN; FACTOR VIII; GUIDELINES; GUIDELINES AS TOPIC; HEMORRHAGE; HUMANS; INFUSIONS, INTRAVENOUS; VON WILLEBRAND DISEASE; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 33749001684     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-949669     Document Type: Review

References (38)

1. Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994;71:520-525
2. Sadler JE, Mannucci PM, Berntorp E, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000;84:160-174
3. Michiels JJ, Van De Velde A, Van Vliet HHDM, Van Der Planken M, Schroyens W, Berneman Z. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications. Semin Thromb Hemost 2002;28:111-131
4. Michiels JJ, Berneman ZW, Gadisseur A, et al. Classification and characterization of hereditary types 2A, 2B, 2M, 2C, 2D, 2E, 2N and 2U (unclassifiable) von Willebrand disease. Clin Appl Thromb Hemost 2006; In press
5. Michiels JJ, Gadisseur A, Budde U, et al. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences. Semin Thromb Hemost 2005;31:577-601
6. Favaloro EJ, Smith J, Petinos P, Hertzberg M, Kouts J. Laboratory testing for von Willebrand's disease: an assessment of current diagnostic practice and efficacy by means of a multi-laboratory survey. Thromb Haemost 1999;82:1276-1282
7. Favaloro EJ. Collagen binding assay for von Willebrand factor (VWF:CBA) detection of von Willebrand disease (VWD) and discrimination of VWD subtypes depends on collagen source. Thromb Haemost 2000;83:127-135
8. Neugebauer BM, Goy C, Budek I, Seitz R. Comparison of two von Willebrand factor collagen-binding assays with different binding affinities for low, medium and high multimers of von Willebrand factor. Semin Thromb Hemost 2002;28:139-147
9. Favaloro EJ, Bukuya M, Martinelli T, et al. A comparative multi-laboratory assessment of three factor/von Willebrand factor concentrates. Thromb Haemost 2002;87:466-476
10. Schneppenheim R, Budde U, Ruggeri ZM. A molecular approach to the classification of von Willebrand disease. Baillieres Clin Haematol 2001;14:281-298
11. Federici AB, Mazurier C, Berntorp E, et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood 2004;103:2032-2038
12. Batlle J, Lopez-Fernandez MF, Campos M, et al. The heterogeneity of type IIA von Willebrand's disease. Blood 1986;68:1207-1215
13. Batlle J, Lassieri J, Villamor AF, et al. Proteolytic processing of von Willebrand factor subunit: heterogeneity in type IIA von Willebrand disease. Ann Hematol 1994;68:111-115
14. Mazurier C, Manucci PM, Parquet-Gernez A, Goudemand , Meyer D. Investigation of a case of subtype IIC von Willebrand disease: characterization of the variability of this subtype. Am J Hematol 1986;22:301-311
15. Eikenboom JCJ, Reitsma PH, Peerlinck KJM, Briët E. Recessive inheritance of von Willebrand's disease. Lancet 1993;341:982-986
16. Schneppenheim R, Budde U, Krey S, et al. Results of a screening for von Willebrand disease type 2N in patients with suspected haemophilia A or von Willebrand disease type 1. Thromb Haemost 1996;76:598-602
17. Mazurier C. Von Willebrand disease masquerading as haemophilia A. Thromb Haemost 1992;67:391-396
18. Mazurier C, Goudemand J, Hilbert L, Caron C, Fressinaud E, Meyer D. Type 2N von Willebrand disease: clinical manifestations, pathophysiology. Laboratory diagnosis and molecular biology. Baillieres Clin Haematol 2001;14:337-347
19. Mazurier C, Gaucher C, Joriuex S, Goudemand M. Biological effect of desmopressin in eight patients with type 2N ('Normandy') von Willebrand disease. Br J Haematol 1994;88:849-854
20. Mannucci PM. Recommended protocol for the study of ex vivo biological effects of virus-inactivated plasma concentrates in patients with von Willebrand disease. Thromb Haemost 1992;68:84-88
21. Mannucci PM, Tenconi PM, Castaman G, Rodeghiero R. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Blood 1992;9:3130-3137
22. Fukui H, Nishino M, Terada S, et al. Hemostatic effect of a heat-treated factor VIII concentrate (Haemate P) in von Willebrand's disease. Blut 1988;56:171-178
23. Lethagen S, Berntorp E, Nilsson IM. Pharmacokinetics and hemostatic effect of different factor VIII-von Willebrand factor concentrates in von Willebrand's disease type III. Ann Hematol 1992;65:253-259
24. Goudemand J, Mazurier C, Marey A, et al. Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity. Br J Haematol 1992;80:214-221
25. Menache D, Aronson DL, Darr F. Montgomery RR and the Cooperative Study Group. Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3): estimation of the rate of factor VIIIC synthesis. Br J Haematol 1996;94:740-745
26. Menache D, Aronson DL. New treatments of von Willebrand disease: plasma derived von Willebrand factor concentrates. Thromb Haemost 1997;78:566-570
27. R). Semin Thromb Hemost 2002;28:203-213
28. Ver Elst K, Van Vliet HHDM, Kappers-Klunne MC, Leebeek FWG. In vitro studies, pharmacokinetic studies and clinical use of a high purity double virus inactivated FVIII/VWF concentrate (Immunate) in the treatment of von Willebrand disease. Thromb Haemost 2004;92:67-74
29. Mannucci PM, Chediak J, Bymes W et al. and the Alphanate Study Group. Treatment of von Willebrand disease with high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 2002;99:450-456
30. Michiels JJ, Berneman ZN, Van Der Planken M, Schroyens W, Budde U, Van Vliet HHDM. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P). Blood Coagul Fibrinolysis 2004;15:323-330
31. Goudemand J, Scharrer I, Berntorp E, et al. Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three visus-inactivation/removal methods. J Thromb Haemost 2005;3:2219-2227
32. Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med 2004;351:683-694
33. Meriane F, Zerhouni L, Djeha N, Goudemand J, Mazurier C. Biological effects of S/D-treated, very high purity, von Willebrand factor concentrate in five patients with severe von Willebrand disease. Blood Coagul Fibrinolysis 1993;4:1023-1029
34. Menache D. Pharmacokinetics of von Willebrand factor and factor VIII coagulant activity in patients with von Willebrand disease type 3 and type 2. Haemophilia 1998;4:44-47
35. Dobrkovska A, Krzensk U, Chediak JR. Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease. Haemophilia 1998;4:33-39
36. Peak IR, Svae E, Kessler C, Berntorp E, Wndyga XX. Actual improvements in the treatment of von Willebrand's disease: Wilate - double virus inactivation, high purity and convenience for patients. Thromb Haemost 2005;95: (Abst)
37. Octapharma. Product brochure Wilate VWF/FVIII- Konzentrat 2005
38. R). Biologicals 2006. In press